Expert perspectives on Myalgic encephalomyelitis/chronic fatigue syndrome - Insights from the 3rd International Conference of the Charité Fatigue Center.

Fehrer, Annick, Windzio, Lara, Schoening, Simon et al. · Autoimmunity reviews · 2026 · DOI

Quick Summary

Nearly 4,000 ME/CFS researchers and experts gathered at an international conference in May 2025 to share the latest discoveries about this serious illness. They discussed how ME/CFS develops, better ways to diagnose it, and new treatments being tested. The conference highlighted that while COVID-19 has brought more attention and funding to ME/CFS research, the disease is still not well understood and needs much more study.

Why It Matters

This summary of expert consensus from a major international conference provides patients and clinicians with a comprehensive overview of current research priorities and emerging understanding of ME/CFS mechanisms. The emphasis on the urgent need for sustained, adequately funded research reflects the scientific community's recognition that ME/CFS causes severe disability yet remains poorly understood compared to other chronic diseases.

Observed Findings

Conference brought together ~200 on-site researchers and ~3,700 online participants from multiple disciplines
Key pathophysiological topics presented included cardiovascular dysregulation, immune dysregulation, autoimmune mechanisms, and metabolic dysfunction
Clinical trials targeting autoantibodies were presented and discussed
Increased public awareness and funding opportunities have emerged following the COVID-19 pandemic
Post-COVID syndrome (PCS) was identified as a major focus alongside classic ME/CFS

Inferred Conclusions

ME/CFS remains severely underresearched despite its significant impact on quality of life and increasing prevalence
Multiple pathophysiological mechanisms are likely involved in ME/CFS, requiring interdisciplinary research approaches
Pandemic-related increases in awareness and funding, while helpful, remain insufficient for adequate investigation
Sustained and adequately funded research efforts are urgently needed to identify diagnostic markers and develop targeted therapies

Remaining Questions

Which pathophysiological mechanisms (cardiovascular, immune, autoimmune, metabolic) are primary versus secondary in ME/CFS pathogenesis?
What biomarkers or diagnostic tests can reliably identify ME/CFS and distinguish it from post-viral conditions like PCS?
Which therapeutic interventions targeting autoantibodies or specific mechanisms show the most promise in clinical trials?
How should healthcare systems be structured to provide optimal care and support for ME/CFS patients?

What This Study Does Not Prove

As an editorial summary of a conference rather than a primary research study, this does not present new experimental data or prove specific diagnostic criteria or treatments are effective. It does not establish causal mechanisms for ME/CFS or validate any single pathophysiological model, but rather reflects expert consensus on areas requiring further investigation.

Topics

Metabolic Dysfunction Post-Exertional Malaise Immune Dysregulation

Metadata

DOI: 10.1016/j.autrev.2026.104043
PMID: 41895458
Review status: Machine draft
Evidence level: Early hypothesis, preprint, editorial, or weak support
Last updated: 7 April 2026